FDA To Expand QT/QTc Prolongation Database
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency is collecting pre-clinical and clinical studies pertaining to QT/QTc prolongation to support a discussion about the use of pre-clinical data. FDA hopes to present the data at the International Conference on Harmonization meeting next year.
You may also be interested in...
QT Prolongation Draft Guidance Urges Single Clinical Trial For Evaluation
The ECG trial should be early in clinical development (but not the first study) should be carried out in healthy volunteers and include a positive control group, FDA’s draft guidance says.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.